Management of hypertriglyceridemia in patients receiving interferon for malignant melanoma

Annals of Pharmacotherapy

Volumn 38, Issue 10, 2004, Pages 1655-1659

  Wong, Siu Fun ^a   Jakowatz, James G ^b   Taheri, Reza ^a,c  

^a W University College of Pharmacy   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c LOMA LINDA UNIVERSITY   (United States)

Author keywords

Hypertriglyceridemia; Interferon ; Malignant melanoma; Management

Indexed keywords

ALPHA INTERFERON; ATORVASTATIN; CHOLESTEROL; GEMFIBROZIL; LIPID; MEVINOLIN; NICOTINIC ACID; TRIACYLGLYCEROL;

ADJUVANT THERAPY; ADULT; ARTICLE; BEHAVIOR MODIFICATION; CARDIOVASCULAR DISEASE; CASE REPORT; CHOLESTEROL BLOOD LEVEL; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DYSLIPIDEMIA; FATIGUE; FEMALE; HUMAN; HYPERTRIGLYCERIDEMIA; LIFESTYLE; MALE; MELANOMA; PRIORITY JOURNAL; PROBABILITY;

ADULT; ANTILIPEMIC AGENTS; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; HYPERTRIGLYCERIDEMIA; INTERFERON-ALPHA; MALE; MELANOMA; MIDDLE AGED; SKIN NEOPLASMS;

EID: 4644235349     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1D546     Document Type: Article

References (27)

1. Weiss K. Safety profile of interferon-alpha therapy. Semin Oncol 1998;25:9-13.
2. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996;14:7-17.
3. Kirkwood JM, Ibrahim JG, Sondak VK, Richards J, Flaherty LE, Ernstoff MS, et al. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 2000;18:2444-58.
4. Berruti A, Gorzegno G, Vitetta G, Tampellini M, Dogliotti L. Hypertriglyceridemia during long-term interferon-alpha therapy: efficacy of diet and gemfibrosil treatment. A case report. Tumori 1992;78:353-5.
5. Ruiz-Moreno M, Carreno V, Rua MJ, Cotonat T, Serrano B, Santos M, et al. Increase in triglycerides during alpha-interferon treatment of chronic viral hepatitis (letter). J Hepatol 1992;16:384.
6. Shinohara E, Yamashita S, Kihara S, Hirano K, Ishigami M, Arai T, et al. Interferon alpha induces disorder of lipid metabolism by lowering post-heparin lipases and cholesteryl ester transfer protein activities in patients with chronic hepatitis C. Hepatology 1997;25:1502-6.
7. Penarrubia MJ, Steegmann JL, Lavilla E, Casado F, Requena MJ, Pico M, et al. Hypertriglyceridemia may be severe in CML patients treated with interferon-alpha. Am J Hematol 1995;49:240-1.
8. Sgarabotto D, Vianello F, Stefani PM, Scano F, Sartori R, Caenazzo A, et al. Hypertriglyceridemia during long-term interferon-alpha therapy in a series of hematologic patients. J Interferon Cytokine Res 1997;17:241-4.
9. Olsen EA, Lichtenstein GR, Wilkinson WE. Changes in serum lipids in patients with condylomata acuminata treated with interferon alfa-n1 (Wellferon). J Am Acad Dermatol 1988;19:286-9.
10. Massaro ER, Borden EC, Hawkins MJ, Wiebe DA, Shrago E. Effects of recombinant interferon-alpha 2 treatment upon lipid concentrations and lipoprotein composition. J Interferon Res 1986;6:655-62.
11. Roguedas AM, Lonceint J, Sassolas B, de Saint Martin L, Guillet G. [Acute pancreatitis after high-dose interferon therapy in a patient with melanoma] French (letter). Presse Med 2001;30:1105.
12. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
13. Austin MA, Hokanson JE, Edwards KL. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol 1998;81:7B-12B.
14. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
15. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). 2001. www.nhlbi.nih.gov/ guidelines/cholesterol/atp3full.pdf (accessed 2004 Jun 30).
16. Eland IA, Rasch MC, Sturkenboom MJ, Bekkering FC, Brouwer JT, Delwaide J, et al. Acute pancreatitis attributed to the use of interferon alfa-2b. Gastroenterology 2000;119:230-3.
17. Grunfeld C, Feingold KR. The role of the cytokines, interferon alpha and tumor necrosis factor in the hypertriglyceridemia and wasting of AIDS. J Nutr 1992;122:749-53.
18. Kurzrock R, Rohde MF, Quesada JR, Gianturco SH, Bradley WA, Sherwin SA, et al. Recombinant gamma interferon induces hypertriglyceridemia and inhibits post-heparin lipase activity in cancer patients. J Exp Med 1986;164:1093-101.
19. Fernandez-Ranada JM, Lavilla E, Odriozola J, Garcia-Larana J, Lozano M, Parody R, et al. Interferon alpha 2A in the treatment of chronic myelogenous leukemia in chronic phase. Results of the Spanish Group. Leuk Lymphoma 1993;11:175-9.
20. Mitchell MS, Kan-Mitchell J, Kempf RA, Harel W, Shau HY, Lind S. Active specific immunotherapy for melanoma: phase I trial of allogeneic lysates and a novel adjuvant. Cancer Res 1988;48:5883-93.
21. Sondak VK, Liu PY, Tuthill RJ, Kempf RA, Unger JM, Sosman JA, et al. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group. J Clin Oncol 2002;20:2058-66.
22. Haskell WL, Alderman EL, Fair JM, Maron DJ, Mackey SF, Superko HR, et al. Effects of intensive multiple risk factor reduction on coronary atherosclerosis and clinical cardiac events in men and women with coronary artery disease. The Stanford Coronary Risk Intervention Project (SCRIP). Circulation 1994;89:975-90.
23. Knopp RH, Walden CE, Retzlaff BM, McCann BS, Dowdy AA, Albers JJ, et al. Long-term cholesterol-lowering effects of 4 fat-restricted diets in hypercholesterolemic and combined hyperlipidemic men. The Dietary Alternatives Study. JAMA 1997;278:1509-15.
24. Roche HM, Gibney MJ. Effect of long-chain n-3 polyunsaturated fatty acids on fasting and postprandial triacylglycerol metabolism. Am J Clin Nutr 2000;71(1 suppl):232S-7S.
25. Harris WS. n-3 fatty acids and serum lipoproteins: human studies. Am J Clin Nutr 1997;65(5 suppl):1645S-54S.
26. Kirkwood JM, Ibrahim JG, Sosman JA, Sondak VK, Agarwala SS, Ernstoff MS, et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol 2001;19:2370-80.
27. Data on file. Kenilworth, NJ: Schering-Plough.